Latest News and Press Releases

BioStem Technologies to Present at the Centri Capital Conference

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 M

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology

BioStem Technologies CEO to Present at Biotech Showcase 2025